Form 4 for VCYT VERACYTE, INC.
Accepted 2021-12-08 00:00:00 ET · period of report 2021-12-06 · accession 0001384101-21-000180 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-12-08 | 2021-12-06+ | VCYT | Kennedy Giulia C | Chief Scientific, Med Off | M - OptEx | $17.97 | +14.3K | 53.4K | +37% | +$256.6K |
| DM | 2021-12-08 | 2021-12-06+ | VCYT | Kennedy Giulia C | Chief Scientific, Med Off | S - Sale+OE | $37.71 | -15.4K | 49.7K | -24% | -$579.1K |
| DM | 2021-12-08 | 2021-12-06+ | VCYT | Kennedy Giulia C | Chief Scientific, Med Off | M - OptEx | $10.82 | -14.3K | 18.8K | -43% | -$154.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-06 | M | A | 3,750 | $20.21 | 57,144 | D | — | — | |
| 2 | Common | Common Stock | 2021-12-06 | S | D | 3,550 | $35.37 | 53,594 | D | — | — | (F2) Represents weighted average sales price. Sale prices for the transactions range from $34.70 to $35.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
| 3 | Common | Common Stock | 2021-12-07 | S | D | 1,750 | $41.55 | 47,912 | D | — | — | |
| 4 | Common | Common Stock | 2021-12-06 | S | D | 1,785 | $37.26 | 47,912 | D | — | — | (F4) Represents weighted average sales price. Sale prices for the transactions range from $36.88 to $37.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
| 5 | Common | Common Stock | 2021-12-07 | M | A | 4,375 | $24.69 | 52,287 | D | — | — | |
| 6 | Common | Common Stock | 2021-12-07 | M | A | 1,750 | $26.55 | 54,037 | D | — | — | |
| 7 | Common | Common Stock | 2021-12-07 | S | D | 4,375 | $39.69 | 49,662 | D | — | — | |
| 8 | Common | Common Stock | 2021-12-06 | M | A | 4,406 | $5.98 | 53,394 | D | — | — | |
| 9 | Common | Common Stock | 2021-12-06 | S | D | 3,897 | $36.11 | 49,697 | D | — | — | (F3) Represents weighted average sales price. Sale prices for the transactions range from $35.79 to $36.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
| 10 | Derivative | Stock Option (right to buy) | 2021-12-06 | M | D | 4,406 | $0.00 | 4,407 | D | $5.98 · — to 2028-03-01 | 4,406 Common Stock | (F5) The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. |
| 11 | Derivative | Stock Option (right to buy) | 2021-12-07 | M | D | 1,750 | $26.55 | 0 | D | $26.55 · — to 2030-05-10 | 1,750 Common Stock | (F8) The option is fully vested. |
| 12 | Derivative | Stock Option (right to buy) | 2021-12-07 | M | D | 4,375 | $24.69 | 39,375 | D | $24.69 · — to 2030-03-27 | 4,375 Common Stock | (F7) The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuousservice thereafter. |
| 13 | Derivative | Stock Option (right to buy) | 2021-12-06 | M | D | 3,750 | $0.00 | 18,750 | D | $20.21 · — to 2029-02-27 | 3,750 Common Stock | (F6) The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. |